RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Royalty Pharma Stock

Royalty Pharma P/E 2024

Royalty Pharma P/E

6.76

Ticker

RPRX

ISIN

GB00BMVP7Y09

WKN

A2P62D

As of Sep 9, 2024, Royalty Pharma's P/E ratio was 6.76, a -61.63% change from the 17.62 P/E ratio recorded in the previous year.

The Royalty Pharma P/E history

Royalty Pharma Aktienanalyse

What does Royalty Pharma do?

Royalty Pharma PLC is a US-based company specializing in investments in biopharmaceutical companies and their products. The company was founded in 1996 by Pablo Legorreta and is headquartered in New York City. It has subsidiaries in Bermuda, Ireland, Luxembourg, and Switzerland. The business model of Royalty Pharma involves providing financial resources to manufacturers of biopharmaceuticals in exchange for a share in the licenses and sales of their products. This allows Royalty Pharma to participate in the development and commercial exploitation of medications without bearing the risk of developing active substances or obtaining approvals. In recent years, Royalty Pharma has invested in a variety of companies to benefit from their commercial success. Examples of companies they work with include Biomarin Pharmaceuticals, Vertex, Teva Pharmaceutical Industries, and General Electric. Royalty Pharma now has a portfolio of over 45 investments in products from companies such as AbbVie, Gilead, Roche, and Amgen. The range of products includes cancer therapies and vaccines, used for both rare diseases and broader applications. One of the most well-known products in Royalty Pharma's portfolio is the cancer drug Kadcyla from Roche. This medication is used in the treatment of breast cancer and has been successful in slowing tumor growth. Another example is the commercial success of the hepatitis C medication Harvoni from Gilead, which improves the quality of life for affected patients and saves lives. Royalty Pharma also has a financing division that focuses on the purchase of existing or future license fees. This division offers credit agreements for biopharmaceutical companies and serves as a good financing alternative for small and medium-sized enterprises. Overall, Royalty Pharma has a successful track record in investing in the biopharmaceutical industry. The model allows the company to benefit from innovative products and their commercial exploitation without taking on the risk of drug development. This allows the company to continue offering attractive returns to its investors. Royalty Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Royalty Pharma's P/E Ratio

The Price to Earnings (P/E) Ratio of Royalty Pharma is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Royalty Pharma's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Royalty Pharma is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Royalty Pharma’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Royalty Pharma stock

What is the price-to-earnings ratio of Royalty Pharma?

The price-earnings ratio of Royalty Pharma is currently 6.76.

How has the price-earnings ratio of Royalty Pharma changed compared to last year?

The price-to-earnings ratio of Royalty Pharma has increased by -61.63% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Royalty Pharma high compared to other companies?

Yes, the price-to-earnings ratio of Royalty Pharma is high compared to other companies.

How does an increase in the price-earnings ratio of Royalty Pharma affect the company?

An increase in the price-earnings ratio of Royalty Pharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Royalty Pharma affect the company?

A decrease in the price-earnings ratio of Royalty Pharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Royalty Pharma?

Some factors that influence the price-earnings ratio of Royalty Pharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Royalty Pharma pay?

Over the past 12 months, Royalty Pharma paid a dividend of 0.8 USD . This corresponds to a dividend yield of about 2.79 %. For the coming 12 months, Royalty Pharma is expected to pay a dividend of 0.78 USD.

What is the dividend yield of Royalty Pharma?

The current dividend yield of Royalty Pharma is 2.79 %.

When does Royalty Pharma pay dividends?

Royalty Pharma pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of Royalty Pharma?

Royalty Pharma paid dividends every year for the past 10 years.

What is the dividend of Royalty Pharma?

For the upcoming 12 months, dividends amounting to 0.78 USD are expected. This corresponds to a dividend yield of 2.71 %.

In which sector is Royalty Pharma located?

Royalty Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Royalty Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Royalty Pharma from 9/13/2024 amounting to 0.21 USD, you needed to have the stock in your portfolio before the ex-date on 8/16/2024.

When did Royalty Pharma pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Royalty Pharma in the year 2023?

In the year 2023, Royalty Pharma distributed 0.76 USD as dividends.

In which currency does Royalty Pharma pay out the dividend?

The dividends of Royalty Pharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Royalty Pharma

Our stock analysis for Royalty Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Royalty Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.